Detalhe da pesquisa
1.
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study).
Lung Cancer
; 193: 107843, 2024 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38830303
2.
ICU admission for solid cancer patients treated with immune checkpoint inhibitors.
Ann Intensive Care
; 13(1): 29, 2023 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37072645
3.
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).
Target Oncol
; 18(6): 905-914, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37966566
4.
Management of patients with synchronous head-and-neck and lung cancers: SYNCHRON GFPC 15-01 study.
J Cancer Res Ther
; 18(Supplement): S160-S164, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36510958
5.
Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study.
Target Oncol
; 17(6): 675-682, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36129569
6.
When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric study.
Bull Cancer
; 109(9): 916-924, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35718570
7.
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study.
Cancers (Basel)
; 14(7)2022 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35406523
8.
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
Lung Cancer
; 136: 109-114, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31491676
9.
Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.
Lung Cancer
; 137: 149-156, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31600593
10.
New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab.
Onco Targets Ther
; 11: 4051-4064, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30038505
11.
Erratum to "When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric study" [Bull. Cancer 109 (2022) 916-24].
Bull Cancer
; 110(4): 467-468, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36805208
12.
Late-Onset Adrenal Insufficiency More Than 1 Year after Stopping Pembrolizumab.
J Thorac Oncol
; 13(3): e39-e40, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29472057
13.
[Supportive cares on thoracic oncology]. / Soins de support en oncologie thoracique.
Bull Cancer
; 99(11): 1057-64, 2012 Nov.
Artigo
em Francês
| MEDLINE | ID: mdl-23073345